-Topline Data Release Targeted Late Summer 2026-

CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense).

An estimated 15 million U.S. adults reported having long COVID between 2022 and 2023, with 3.8 million experiencing significant limitation to their daily lives. Almost 50 percent of those with Long COVID develop persistent or intermittent symptoms. The neurological and neuropsychiatric symptoms are among the most common and disabling manifestations of the condition and include fatigue, persistent cognitive dysfunction, post-exertional malaise and sleep disturbance. Currently, there are no FDA-approved treatment options.